In the typical early symptomatic AD trial, we expect to see relatively small progression in plasma p-tau levels, and an effective treatment is expected to reduce soluble p-tau levels in plasma below the levels that exist at baseline (Figure 1). The gene discussed is MAPT; the disease is Alzheimer disease.